Histogen Past Earnings Performance
Past criteria checks 0/6
Histogen's earnings have been declining at an average annual rate of -9.7%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 36.7% per year.
Key information
-9.7%
Earnings growth rate
54.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -36.7% |
| Return on equity | -281.2% |
| Net Margin | -65,142.1% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Histogen stock down 8% after Q2 loss, on track for six-day losing streak
Aug 12Histogen announces pricing of $5M private placement
Jul 12We're A Little Worried About Histogen's (NASDAQ:HSTO) Cash Burn Rate
Dec 02
Histogen jumps 11% after Intracoastal Capital reports 5.6% stake
Jun 16Histogen enters $6.5M at-the-market direct offering
Jun 07Histogen under pressure on pricing $14M upsized public offering
Dec 31Histogen files IND application for regenerative human matrix
Dec 17Histogen soars after HST-001 data in male pattern baldness
Dec 01Revenue & Expenses BreakdownBeta
How Histogen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -12 | 9 | -2 |
| 30 Jun 23 | 0 | -12 | 9 | 0 |
| 31 Mar 23 | 0 | -14 | 9 | 0 |
| 31 Dec 22 | 4 | -11 | 9 | 0 |
| 30 Sep 22 | 4 | -11 | 9 | 4 |
| 30 Jun 22 | 4 | -12 | 8 | 0 |
| 31 Mar 22 | 4 | -11 | 8 | 0 |
| 31 Dec 21 | 1 | -15 | 8 | 0 |
| 30 Sep 21 | 2 | -15 | 8 | 0 |
| 30 Jun 21 | 1 | -15 | 8 | 0 |
| 31 Mar 21 | 2 | -21 | 8 | 0 |
| 31 Dec 20 | 2 | -19 | 7 | 0 |
| 30 Sep 20 | 3 | -18 | 7 | 0 |
| 30 Jun 20 | 3 | -15 | 6 | 0 |
| 31 Mar 20 | 4 | -9 | 6 | 0 |
| 31 Dec 19 | 11 | -3 | 6 | 0 |
| 30 Sep 19 | 10 | -2 | 5 | 0 |
| 31 Dec 18 | 2 | -6 | 3 | 0 |
| 31 Dec 17 | 10 | 2 | 3 | 0 |
Quality Earnings: HSTO is currently unprofitable.
Growing Profit Margin: HSTO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HSTO is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare HSTO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HSTO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.9%).
Return on Equity
High ROE: HSTO has a negative Return on Equity (-281.18%), as it is currently unprofitable.